dc.contributorTrillos, Carlos Enrique
dc.contributorAnaya, Juan-Manuel
dc.creatorSánchez-Cuervo, Janneth
dc.date.accessioned2018-10-16T15:14:24Z
dc.date.available2018-10-16T15:14:24Z
dc.date.created2018-10-16T15:14:24Z
dc.date.issued2018
dc.identifierhttp://repository.urosario.edu.co/handle/10336/18640
dc.description.abstractIntroduction: Rheumatic autoimmune diseases (ARDs) affect mainly women in fertile age. They can be associated with genetic, hormonal or environmental factors. In Colombia, oral contraceptives are the second in use by women between 13 and 49 years. The objective of this paper is to describe the habits of contraception in women with (ARDs) and to explore the factors associated with contraception. Methods: this was cross-sectional exploratory study in which a self-report survey was applied to investigate the contraceptive practices and gyneco-obstetric history. Univariate and bivariate analyses were done. The statistical tests X2 and Kruskal-Wallis were done. Results: Of the 188 women followed by the rheumatologist during 2017, 57 were in fertile age. The mean age was 36,7 ± 7,4 with a mean age at disease onset of 25,5 ± 7,5. Of the included patients, 24.6% were diagnosed with rheumatoid arthritis, 54.4% with systemic lupus eruthematosus, 12.2% with systemic sclerosis and 8.8% with Sjögren´s syndrome. Polyautoimmunity (i.e, two or more simultaneous autoimmune diseases) was observed in 10.5% of patients. The most frequently used contraceptive methods were: definite (33.3%), oral contraceptives (24.6%), barrier (1.7%) and natural or no contraception (28.1%). The age at disease onset was associated with the civil status (p=0.004) and the presence of ARD (p<0.001). The definite contraceptive method was associated with polyautoimmunity (p=0.03) and the level of education (p=0.01). Other contraceptive methods showed no significant associations. Conclusions: women with ARDs use mostly definite contraception methods which appears to have high safety and efficacy in these patients. The use of oral contraceptives shows a minimal risk in these patients.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherFacultad de medicina
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.sourceDuarte C, Inês L. Oral contraceptives and systemic lupus erythematosus: What should we advise to our patients? Acta Reumatol Port. 2010;35(2):133–40.
dc.sourceAnaya J, García-carrasco M, Cervera R. Autoinmunidad y Enfermedad Autoinmune. Med Interna (Bucur). 2005;546.
dc.sourceQuintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. Elsevier Ltd; 2012;38(2–3):J109–19.
dc.sourceCutolo M, Wilder RL. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum Dis Clin North Am. 2000;26(4):825–39.
dc.sourceMinisterio de Salud y, Profamilia. Encuesta Nacional de Demografía y Salud 2015 Resumen Ejecutivo. 2016;1–96.
dc.sourceAnaya J-M, Rojas-Villarraga A. La tautología autoinmune. Editorial Universidad del Rosario; 2012. 304 p.
dc.sourceFarr S, Folger S, Paulen M, Curtis K. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contracept J. 2010;64–71.
dc.sourceRose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today. 1993;14(9):426–30.
dc.sourceBowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol. 2004;33(1):39–43.
dc.sourceDanza Á, Ruiz-Irastorza G, Khamashta M. El embarazo en las enfermedades autoinmunes sistémicas: mitos, certezas y dudas. Med Clin (Barc). SEGO; 2016;147(7):306–12.
dc.sourceBrowne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2009;6(3):247–53.
dc.sourceStringer EM, Kaseba C, Levy J, Goldenberg RL, Chi BH, Matongo I, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197(2):1–16.
dc.sourceClowse MEB, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514–21.
dc.sourceClowse MEB, Chakravarty E, Costenbader KH, Chambers C, Michaud K. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(5):668–74.
dc.sourceRojas-Villarraga A, Torres-Gonzalez J-V, Ruiz-Sternberg Á-M. Safety of Hormonal Replacement Therapy and Oral Contraceptives in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. PLoS One. 2014;9(8):e104303.
dc.sourceSiamopoulou-Mavridou A, Manoussakis MN, Mavridis AK, Moutsopoulos HM. Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset. Ann Rheum Dis. 1988;47(12):982–7.
dc.sourceMayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999;107 Suppl(Suppl 5):743–8.
dc.sourceKobak Ş, Hacivelioglu S, Gungor S. Scleroderma renal crisis and ovarian hyperstimulation syndrome related to the use of clomiphene in a patient with scleroderma. Reumatol Clin. 2014;10(1):51–3.
dc.sourceYazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ. Contraceptive Counseling and Use Among Women with Systemic Lupus Erythematosus: A Gap in Health Care Quality? 2011;63(3):358–65.
dc.sourceGenerini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am. 2005;31(1):177–86.
dc.sourceøstensen M. Connective tissue diseases: Contraception counseling in SLE-an often forgotten duty? Nat Rev Rheumatol. Nature Publishing Group; 2011;7(6):315–6.
dc.sourceReferral GFOR, Of M, Lupus S, In E. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999;42(9):1785–96.
dc.sourceArnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Vol. 31, Arthritis & Rheumatism. 1988. p. 315–24.
dc.sourceVitali C, Bombardieri S, Jonsson R, Moutsopoulos HM A, Al. E et. Classification criteria for Sjögren’s syndrome: a revised version of the Erupean criteria proposed by the American- European Consensus Group. Ann Rheum Dis. 2002;61:554–8.
dc.sourceHoogen F Van Den, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.
dc.sourceAndreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–85.
dc.sourceSanchez-Guerrero J, Jimenez- Santana L, Mestanza-Peralta Ma, Lara-Reyes P. A Trial of Contraceptive Methods in Women with Systemic Lupus Erythematosus Jorge. N Engl J Med. 2005;353(24):2539–49.
dc.sourcePetri, M Kim, MY Kalunian K. Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. N Engl J Med. 2005;353(24):2550–8.
dc.sourceMăluțan A, Ciortea R, Porumb C, Florin Mocan-Hognogi R, Bucuri C, Bobric A, et al. Hormonal contraception in women with autoimmune diseases. Gineco.ro. 2015;11:141–7.
dc.sourceLi RHW, Gebbie AE, Wong RWS, Ng EHY, Glasier AF, Ho PC. The use of sex hormones in women with rheumatological diseases. Hong Kong Med J. 2011;17(6):487–91.
dc.sourcePetri M. Musculoskeletal complications of systemic lupus erythematosus in the hopkins lupus cohort: An update. Arthritis Rheum. 1995;8(3):137–45.
dc.sourceRamsey-Goldman R, Dunn JE, Huang C-F, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: Comparison with united states population data. Arthritis Rheum. 1999;42(5):882–90.
dc.sourceOrganización mundial de la salud. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346(8990):1575–82.
dc.subjectEnfermedades reumáticas
dc.subjectEnfermedades autoinmunes
dc.subjectEnfermedad reumática autoinmune
dc.subjectArtritis reumatoide
dc.subjectLupus eritematoso sistémico
dc.subjectSíndrome de Sjögren
dc.subjectEsclerosis sistémica
dc.subjectAnticoncepción
dc.subjectAnticonceptivos hormonales
dc.titlePrácticas de anticoncepción en mujeres con enfermedad reumática autoinmune en Bogota, D.C., Colombia, 2017
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución